Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Yonghyun KimEun Seok KangHak Chul JangDong Jun KimTaekeun OhEun Sook KimNan Hee KimKyung Mook ChoiSung-Rae KimJiYoung YouSe-Jin KimMoon-Kyu LeePublished in: Diabetes, obesity & metabolism (2018)
Teneligliptin was non-inferior to sitagliptin in the context of triple therapy for T2DM and is an important option in this setting.